Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Well, the original question (if you follow the ent

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155054
(Total Views: 524)
Posted On: 05/15/2020 1:36:13 PM
Posted By: dejavu
Re: tconway1118 #34155
Well, the original question (if you follow the entire thread.. I'm just going to repost because nobody is doing much of anything except responding to single posts out of context):

Quote:

Just a random thought that came up. From what I know childhood cancers tends to be more aggressive and progress more rapidly than adult cancers. Could that mean that kids express the CCR5 receptor more than adults do? If so.. most likely kids will respond even better to Leronlimab compared to adults.

Read More: https://investorshangout.com/post/view?id=576...z6MX58jgc7



This was my response:

Quote:

I'd think if there was more CCR5 expression in kids, they'd be hit harder by CV... the Kawasaki-like syndrome is serious, not downplaying that, but they don't seem to have cardiac, pulmonary, and clotting issues. (Those may have more to do with ACE2). Leaky blood vessels and inflammation seem to be how younger people present.

Read More: https://investorshangout.com/post/view?id=576...z6MX5XS5HR



Which is the point of the original hypothesis... epigenetics of juvenile / adult expression of CCR5 as it pertains to CV infection and treatment.

"The kid dies, it doesn't matter how" is pretty much the antithesis of scientific inquiry... I'm not sure what your point is, either. I think there's a decent chance Leronlimab will have a similar, positive impact on juvenile COVID patients as well, but the fact they are presenting so differently from adult cases could have a significant effect on whether that turns out to be the case or not.


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us